Sumit Verma

Sumit Verma is the founding Chief Executive Officer (CEO) for TAG1 inc. – a premier supplier of medical radioisotopes that will be used for Radioligand Therapies (RLTs). He also serves as co-founder of Orchestra Life Sciences, a technical advisory team that is in the forefront of providing scientific and strategic support in the development and commercialization of advanced therapies for cancer and rare diseases. Sumit most recently served as Senior Vice President Global Strategy and Manufacturing for Iovance Biotherapeutics where he had executive responsibilities for building a new cell therapy manufacturing facility, the Iovance Cell Therapy Center (iCTC), in The Navy Yard Philadelphia. He formed the commercial manufacturing organization at iCTC that has achieved significant milestones including the accelerated FDA approval of Amtagvi ™ – the world’s 1st approved solid tumor cell therapy. Verma has successfully built and led technical and manufacturing organization for five FDA-approved therapeutic launches over the past 25 years: AMTAGVI™, Ultra-Technekow™ V4 (Technetium Tc 99m) Generator, Sestamibi™, Proquad Vaccine ™ and Detectnet™ . He has also led teams in the development and launch of Xenon-133 Gas, Germanium-68, LEU Molybdenum-99 and I-123 gas medical isotopes. Prior to Iovance, he has had multiple leadership roles at Merck and Co., Covidien, Mallinckrodt and served as the Chief Operating Officer (COO) for Curium Pharmaceuticals. Sumit received his Bachelor of Science in Chemical Engineering from Lafayette College and Masters in Engineering from Washington University in St. Louis.